| Drug General Information |
| Drug ID |
D02AYL
|
| Former ID |
DNC001088
|
| Drug Name |
PA-824
|
| Drug Type |
Small molecular drug
|
| Indication |
Mycobacterium tuberculosis infection [ICD10:A15-A19]
|
Phase 3 |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C14H12F3N3O5
|
| Canonical SMILES |
C1C(COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F
|
| InChI |
1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1
|
| InChIKey |
ZLHZLMOSPGACSZ-NSHDSACASA-N
|
| CAS Number |
CAS 187235-37-6
|
| PubChem Compound ID |
|
| PubChem Substance ID |
602759, 11568219, 14754667, 56314347, 74512488, 92309397, 103516892, 109718929, 129919200, 134340334, 135143585, 136345878, 136348779, 136967299, 139347532, 144229765, 162223093, 162474735, 164046419, 164764023, 174006653, 174007389, 175426953, 179231147, 188889470, 196409666, 198982738, 210274726, 210280360, 223384013, 223554904, 223700553, 223705177, 223726250, 229040932, 241383546, 249855633, 250224263, 251971002, 252066562, 252434136, 252450233, 252553552
|
| Target and Pathway |
| Target(s) |
Fatty acid synthase |
Target Info |
Inhibitor |
[2]
|
|---|
|
BioCyc Pathway
|
Fatty acid biosynthesis initiation
|
|
Fatty acid elongation -- saturated
|
|
Palmitate biosynthesis
|
|
KEGG Pathway
|
Fatty acid biosynthesis
|
|
Metabolic pathways
|
|
Fatty acid metabolism
|
|
AMPK signaling pathway
|
|
Insulin signaling pathway
|
|
Pathway Interaction Database
|
p73 transcription factor network
|
|
Validated transcriptional targets of deltaNp63 isoforms
|
|
PathWhiz Pathway
|
Fatty Acid Biosynthesis
|
|
Reactome
|
ChREBP activates metabolic gene expression
|
|
Activation of gene expression by SREBF (SREBP)
|
|
Fatty Acyl-CoA Biosynthesis
|
|
WikiPathways
|
Fatty Acid Biosynthesis
|
|
Nuclear Receptors Meta-Pathway
|
|
Liver X Receptor Pathway
|
|
Activation of Gene Expression by SREBP (SREBF)
|
|
SREBF and miR33 in cholesterol and lipid homeostasis
|
|
SREBP signalling
|
|
Metabolism of water-soluble vitamins and cofactors
|
|
Integration of energy metabolism
|
|
Fatty acid, triacylglycerol, and ketone body metabolism
|
|
AMPK Signaling
|
| References |
| REF 1 | ClinicalTrials.gov (NCT02342886) Shortening Treatment by Advancing Novel Drugs. U.S. National Institutes of Health. |
|---|
| REF 2 | Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8. |
|---|
